Nexalis Therapeutics Limited (ASX:NX1)

Market Cap	6.33M +15.0%
Revenue (ttm)	767.69K +91.1%
Net Income	-1.83M
EPS	-0.01
Shares Out	253.04M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	35,714
Average Volume	302,236
Open	0.0250
Previous Close	n/a
Day's Range	0.0250 - 0.0250
52-Week Range	0.0180 - 0.0480
Beta	-0.29
RSI	50.08
Earnings Date	Feb 27, 2026

About Nexalis Therapeutics

Nexalis Therapeutics Limited, a biotechnology company, develops and sells registrable inhaled drug-device combinations in Australia. It is developing IRX-211 that has completed Phase 1 clinical trial for the treatment of Breakthrough Cancer Pain (BTcP); and IRX-616a that is in preclinical trial for panic disorder (PD). The company was formerly known as InhaleRx Limited and changed its name Nexalis Therapeutics Limited in January 2026. Nexalis Therapeutics Limited was incorporated in 2016 and is headquartered in Melbourne, Australia.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: NX1

Financial Performance

In 2025, Nexalis Therapeutics's revenue was 767,691, an increase of 91.06% compared to the previous year's 401,811. Losses were -1.83 million, 51.3% more than in 2024.